Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia

Journal of Thrombosis and Haemostasis : JTH
Jin ZhouG E Gilbert


Acute promyelocytic leukemia (APL) frequently causes disseminated intravascular coagulation that can worsen with cytotoxic chemotherapy but improve with the therapeutic differentiating agents, all trans retinoic acid (ATRA) and arsenic trioxide (As(2)O(3)). APL cells display tissue factor but the relationship of tissue factor and other procoagulant activity to phosphatidylserine (PS) exposure is largely unknown. Lactadherin, a milk protein with stereospecific binding to phosphatidyl-L-serine, was used as a probe for PS exposure on an immortalized APL cell line (NB4) and on the cells of eight patients with APL. PS exposure was evaluated with flow cytometry, confocal microscopy, coagulation assays, and purified prothrombinase and factor (F) Xase assays. Plasma procoagulant activity of NB4 and APL cells increased approximately 15-fold after exposure to etoposide or daunorubicin and decreased 80% after treatment with ATRA or As(2)O(3). Procoagulant activity corresponded to exposed PS on viable APL cells. PS exposure decreased after treatment with ATRA or As(2)O(3) and increased after treatment with daunorubicin or etoposide. Excess lactadherin inhibited 80-85% of intrinsic FXase, FVIIa-tissue factor and prothrombinase activities on...Continue Reading


May 16, 2014·Pharmaceuticals·Guangshun Wang
Nov 26, 2013·Nuclear Medicine and Biology·Runa H PoulsenMichael Rehling
Sep 26, 2012·Journal of Thrombosis and Haemostasis : JTH·L V M Rao, U R Pendurthi
Mar 27, 2016·Journal of Experimental & Clinical Cancer Research : CR·Liangliang ZhaoDaxun Piao
May 21, 2016·Liver International : Official Journal of the International Association for the Study of the Liver·Xiaoming WuJialan Shi
Oct 16, 2015·Biomarkers in Cancer·Shosaku NomuraMichiomi Shimizu
Jul 19, 2017·Cancer Biology & Therapy·Ruishuang MaJialan Shi


Apr 1, 1999·The New England Journal of Medicine·J S MenellK A Hajjar
May 23, 2000·Biochemistry·M H AndersenJan T Rasmussen
Nov 13, 2001·British Journal of Haematology·J WangH C Kwaan
Mar 29, 2002·Hematological Oncology·Hau C KwaanLisa N Boggio
Sep 5, 2002·Nature Reviews. Cancer·Jun ZhuHugues de Thé
Sep 24, 2004·The Journal of Biological Chemistry·Heidi KenisChris P M Reutelingsperger
Nov 10, 2004·Biochimica Et Biophysica Acta·Jialan ShiG E Gilbert
Feb 12, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Ian del CondeNeal S Kleiman
Jan 7, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Ronald R Bach
Nov 24, 2006·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Jialan ShiG E Gilbert
May 20, 2008·Journal of Thrombosis and Haemostasis : JTH·Jialan ShiG E Gilbert

Related Concepts

Flow Cytometry
Antineoplastic Agents
Cancer procoagulant
Annexin A5
Disseminated Intravascular Coagulation
PAS-7 glycoprotein, Bos taurus
ANXA5 gene

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.